IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
NCT05989711 on ClinicalTrials.gov · last registry update 2026-05-18
Finished 25 November 2025, after enrolling 212 people. pemvidutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- pemvidutide
- Sponsor
- Altimmune, Inc.
- Sponsor type
- Industry
- Enrollment
- 212
- Started
- 2023-07-27
- Primary completion
- 2025-11-25 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis
Conditions studied
Non-Alcoholic Steatohepatitis (NASH)
Every field above is taken directly from the registry record. See all detected changes across the class, or the pemvidutide page for this molecule’s full trial and approval history.